Literature DB >> 20505440

Donepezil-associated bradyarrhythmia in a patient with dementia with Lewy bodies (DLB).

Michael H Rosenbloom1, Richard Finley, Melvin M Scheinman, Mitchell D Feldman, Bruce L Miller, Gil D Rabinovici.   

Abstract

Dementia with Lewy bodies (DLB) is a neurodegenerative condition that results in loss of mesopontine cholinergic neurons and sympathetic deinnervation. Although acetylcholinesterase inhibitors have been shown to improve cognitive and behavioral deficits in DLB, these patients may be more susceptible to bradyarrhythmic side effects from this class of drugs due to the autonomic insufficiency associated with the disease. We present a patient who experienced a dose-dependent, symptomatic sinus bradyarrhythmia with donepezil doses at and greater than 5 mg. Owing to underlying autonomic dysfunction, patients with DLB may be at increased risk of bradyarrhythmia resulting from treatment with acetylcholinesterase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20505440      PMCID: PMC2879079          DOI: 10.1097/WAD.0b013e3181b7642b

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  10 in total

1.  Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias.

Authors:  C Ballard; R Lane; P Barone; R Ferrara; S Tekin
Journal:  Int J Clin Pract       Date:  2006-06       Impact factor: 2.503

2.  The acetylcholinesterase inhibitors for treatment of cognitive and behavioral symptoms in dementia with Lewy bodies.

Authors:  Martine Simard; Robert van Reekum
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2004       Impact factor: 2.198

3.  [Symptomatic sinus bradycardia associated with donepezil].

Authors:  J M Calvo-Romero; J L Ramos-Salado
Journal:  Rev Neurol       Date:  1999 Jun 1-15       Impact factor: 0.870

4.  Complete atrioventricular block and ventricular tachyarrhythmia associated with donepezil.

Authors:  T Suleyman; P Tevfik; G Abdulkadir; S Ozlem
Journal:  Emerg Med J       Date:  2006-08       Impact factor: 2.740

5.  A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies.

Authors:  Alan J Thomas; David J Burn; Elise N Rowan; Elizabeth Littlewood; Jane Newby; David Cousins; Sanjeet Pakrasi; Jonathan Richardson; Jonathan Sanders; Ian G McKeith
Journal:  Int J Geriatr Psychiatry       Date:  2005-10       Impact factor: 3.485

6.  Cardiac (123)I-meta-iodobenzylguanidine (MIBG) uptake in dementia with Lewy bodies: comparison with Alzheimer's disease.

Authors:  H Watanabe; T Ieda; T Katayama; A Takeda; I Aiba; M Doyu; M Hirayama; G Sobue
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-06       Impact factor: 10.154

7.  Donepezil overdose: a tenfold dosing error.

Authors:  G Shepherd; W Klein-Schwartz; R Edwards
Journal:  Ann Pharmacother       Date:  1999 Jul-Aug       Impact factor: 3.154

8.  Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons.

Authors:  Sultan Darvesh; Rakesh C Arora; Earl Martin; David Magee; David A Hopkins; J Andrew Armour
Journal:  Exp Neurol       Date:  2004-08       Impact factor: 5.330

9.  Significance of syncope in patients with Alzheimer's disease treated with cholinesterase inhibitors.

Authors:  P Bordier; S Garrigue; S S Barold; N Bressolles; S Lanusse; J Clémenty
Journal:  Europace       Date:  2003-10       Impact factor: 5.214

Review 10.  Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.

Authors:  I G McKeith; D W Dickson; J Lowe; M Emre; J T O'Brien; H Feldman; J Cummings; J E Duda; C Lippa; E K Perry; D Aarsland; H Arai; C G Ballard; B Boeve; D J Burn; D Costa; T Del Ser; B Dubois; D Galasko; S Gauthier; C G Goetz; E Gomez-Tortosa; G Halliday; L A Hansen; J Hardy; T Iwatsubo; R N Kalaria; D Kaufer; R A Kenny; A Korczyn; K Kosaka; V M Y Lee; A Lees; I Litvan; E Londos; O L Lopez; S Minoshima; Y Mizuno; J A Molina; E B Mukaetova-Ladinska; F Pasquier; R H Perry; J B Schulz; J Q Trojanowski; M Yamada
Journal:  Neurology       Date:  2005-10-19       Impact factor: 9.910

  10 in total
  2 in total

1.  Effectiveness of rivastigmine on positive, negative, and cognitive symptoms of schizophrenia: a double-blind clinical trial.

Authors:  Saeed Shoja Shafti; Abbas Azizi Khoei
Journal:  Ther Adv Psychopharmacol       Date:  2016-09-14

2.  Comprehensive treatment of dementia with Lewy bodies.

Authors:  Brendon P Boot
Journal:  Alzheimers Res Ther       Date:  2015-05-29       Impact factor: 6.982

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.